Latanoprost

USDailyMed:Latanoprost AU:B3 S01EE01(WHO)S01EE51(WHO),S01EE52(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- [(3R)3-hydroxy-5-phenylpentyl]-cyclopentyl] hept-5-enoate 130209-82-4Y 5311221 1961 DB00654Y 4470740Y 6Z5B6HVF6O D00356Y CHEBI:6384Y ChEMBL1051Y DTXSID1041057 Interactive image O=C(OC(C)C)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCc1ccccc1 InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1YKey:GGXICVAJURFBLW-CEYXHVGTSA-NY Latanoprost, sold under the brand nameXalatanamong others, is a medication used to treat increasedpressure inside the eye(intraocular pressure).This includesocular hypertensionandopen-angle glaucoma.Latanaprost is applied aseye dropsto theeyes.Onset of effects is usually within four hours, and they last for up to a day. Common side effects includeblurry vision, redness of the eye, itchiness, and darkening of theiris.Latanoprost is in theprostaglandin analoguefamily of medications.It works by increasing the outflow ofaqueous fluidfrom the eyes through theuveoscleral tract. Latanoprost was approved for medical use in the United States and the European Union in 1996.It is on theWorld Health Organization's List of Essential Medicines.Latanoprost is available as ageneric medication.In 2023, it was the 67th most commonly prescribed medication in the United States, with more than 9million prescriptions.It is available as afixed-dose combinationwithnetarsudilasnetarsudil/latanoprostand withtimololaslatanoprost/timolol.